Larka acted as M&A strategic advisor to Keensight Capital on its investment in Biovian.
04 June 2018
Larka is pleased to announce that it performed the Strategic Due-Diligence for Keensight Capital and Edmond de Rothschild Equity Strategies (ERES), the new shareholders of Biovian. Larka M&A services advised Keensight Capital and ERES on all relevant strategic, commercial and business aspects of the transaction.
Keensight Capital acquired a majority stake in Biovian, a leading European player in contract development and manufacturing of biopharmaceuticals, alongside the founders, the managers and ERES funds.
Founded in 2003 and based in Turku, Finland, Biovian has 70 employees and offers outsourcing services in process development and contract manufacturing for small and medium size biotechnology covering all the stages of the drug development lifecycle.
Larka, as strategic advisor in M&A, performed the Strategic Due-Diligence to support the new shareholders during the acquisition of Biovian.
Pierre-Anthony Brioir, Senior Manager at Larka, commented: ”We are proud to have collaborated as strategic advisors with Keensight during this M&A process and very happy they have won this deal which attracted many PE and industrial players. Biovian’s management has created a strong company with a smart and flexible approach of the CDMO business which offers multiple levers of value creation. Combined with the very skilled and experienced team of Keensight, Biovian will become a leading player of the Contract Development business in Europe in the near future.”
Pierre-Anthony Brioir, Senior manager at Larka, +33 650-630-286, email@example.com
Adrien Chalmont, Manager at Larka, +33 621-006-115, firstname.lastname@example.org
Founded in 1993, Larka is an “Industry & Strategy” consulting and M&A advisory firm exclusively dedicated to the Pharma & Biotech industry. Larka combines strong value-creation strategic advisory with in-depth industrial & technical expertise. With over 100 consultants, Larka covers the whole value chain and helps Private Equity Firms, Pharma & Biotech companies, and Contract Services Providers – Analytical testing Labs, CROs, CDMOs, CMOs – build sustainable and profitable businesses globally.
About Keensight Capital
Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For almost 20 years now, their team of seasoned professionals have leveraged their knowledge in investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million. Drawing on their expertise in the sectors of Information Technology/Internet and Healthcare/Wellbeing, they identify the best investment opportunities in Europe and work closely with management teams to develop and achieve their strategic vision.